Clinical Trial

The Efficacy of Neoadjuvant Chemoradiotherapy in Comparison With Neoadjuvant Chemotherapy in Patients With Resectable Squamous Cell Esophageal Cancer

Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated October 4, 2022 (before its estimated September 14, 2025 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to evaluate the safety, feasibility and outcomes of neoadjuvant chemotherapy followed by esophagectomy versus neoadjuvant chemoradiotherapy followed by esophagectomy for locally advanced resectable esophageal squamous cell carcinoma cT3-4aN0M0, cT1-4aN1-3M0. This is non-inferiority study (neoadjuvant chemoradiotherapy has no advantage over neoadjuvant chemotherapy).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2022-09-19.
Trial Details
NCT Number NCT05547529
Lead Sponsor Blokhin's Russian Cancer Research Center
Conditions Esophageal Cancer
Enrollment 156 participants
Start Date 2022-09-14
Primary Completion 2025-09-14 (estimated)
Study Completion 2027-09-14 (estimated)
Updated on ClinicalTrials.gov 2022-10-04